WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Zug, Switzerland, May 4, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the first quarter of 2017 on Thursday, May 11, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the Company's financial results and to provide a general business update.
To participate in this conference call, dial 1-877-280-3459 (USA) or +1-646-254-3374 (International), and enter passcode 5733572. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]
